ALPMF News and Press, Astellas Pharma Inc From 08/09/19

Results from the Phase 3 FLAURA study evaluating AstraZeneca's (NYSE: AZN ) Tagrisso (osimertinib) in treatment-naive patients with locally advanced/metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) showed a statistically significant improvement in overall survival (O...

AstraZeneca (NYSE: AZN ) and collaboration partner Merck (NYSE: MRK ) announce positive results from a Phase 3 clinical trial, PROfound , evaluating PARP inhibitor Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) with a certain genetic profile called...

Read more ...

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Astellas Pharma ( OTCPK:ALPMF ) inks an agreement with Woburn, MA-based Frequency Therapeutics  to co-develop and commercialize a regenerative therapeutic candidate, FX-322, for the treatment of sensorineural hearing loss. More news on: Astellas Pharma Inc., Astellas Pharma Inc., H...

Nano cap Aevi Genomic Medicine (NASDAQ: GNMX ) is up  23%  after hours on the heels of its exclusive in-license agreement with Astellas Pharma ( OTCPK:ALPMF ) unit OSI Pharmaceuticals securing global development and commercialization rights to ASP7486 (formerly OSI-027). More n...

Recently in the journal Nature , an article was published characterizing the oldest known example of a fungus. The organism, termed an Ourasphaira, was approximately one billion years old and was found in what was believed to be an ancient river bed in Canada. For comparison sake, the oldes...

Seattle Genetics (NASDAQ: SGEN ) and Astellas Pharma ( OTCPK:ALPMF )  announces  positive topline results from the first cohort of patients enrolling 128 patients in a phase 2 single-arm clinical trial known as EV-201. More news on: Seattle Genetics, Inc., Astellas Phar...

Quick Take Anchiano Therapeutics ( ANCN ) intends to raise $35 million in a U.S. IPO, per an amended regulatory filing . The company is developing a single biologic candidate to treat bladder and other cancers. ANCN has had promising trial results, strong existing investor support of th...

Read more ...